Your browser doesn't support javascript.
loading
Infections in the era of immunobiologicals
Romiti, Ricardo; Hirayama, André Luís da Silva; Porro, Adriana Maria; Gonçalves, Heitor de Sá; Miot, Luciane Donida Bartoli; Durães, Sandra Maria Barbosa; Marques, Silvio Alencar.
Afiliación
  • Romiti, Ricardo; Universidade de São Paulo. Hospital das Clínicas. Department of Dermatology. São Paulo. BR
  • Hirayama, André Luís da Silva; Universidade de São Paulo. Hospital das Clínicas. Department of Dermatology. São Paulo. BR
  • Porro, Adriana Maria; Universidade Federal de São Paulo. Escola Paulista de Medicina. Department of Dermatology. São Paulo. BR
  • Gonçalves, Heitor de Sá; Centro de Dermatologia Dona Libânia. State Health Secretariat of Ceará. Fortaleza. BR
  • Miot, Luciane Donida Bartoli; Universidade Estadual Paulista. Faculty of Medicine. Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy. Botucatu. BR
  • Durães, Sandra Maria Barbosa; Universidade Federal Fluminense. Faculty of Medicine. Department of Internal Medicine, Dermatology Unit. Niterói. BR
  • Marques, Silvio Alencar; Universidade Estadual Paulista. Faculty of Medicine. Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy. Botucatu. BR
An. bras. dermatol ; An. bras. dermatol;99(2): 167-180, Mar.-Apr. 2024. tab, graf
Article en En | LILACS-Express | LILACS | ID: biblio-1556829
Biblioteca responsable: BR1.1
ABSTRACT
Abstract Immunobiologicals represent an innovative therapeutic option in dermatology. They are indicated in severe and refractory cases of different diseases when there is contraindication, intolerance, or failure of conventional systemic therapy and in cases with significant impairment of patient quality of life. The main immunobiologicals used in dermatology basically include inhibitors of tumor necrosis factor-alpha (anti-TNF), inhibitors of interleukin-12 and -23 (anti-IL12/23), inhibitors of interleukin-17 and its receptor (anti-IL17), inhibitors of interleukin-23 (anti-IL23), rituximab (anti-CD20 antibody), dupilumab (anti-IL4/IL13) and intravenous immunoglobulin. Their immunomodulatory action may be associated with an increase in the risk of infections in the short and long term, and each case must be assessed individually, according to the risk inherent to the drug, the patient general condition, and the need for precautions. This article will discuss the main risks of infection associated with the use of immunobiologicals, addressing the risk in immunocompetent and immunosuppressed patients, vaccination, fungal infections, tuberculosis, leprosy, and viral hepatitis, and how to manage the patient in the most diverse scenarios.
Palabras clave

Texto completo: 1 Bases de datos: LILACS Idioma: En Revista: An. bras. dermatol Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Bases de datos: LILACS Idioma: En Revista: An. bras. dermatol Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Brasil